Evaluation of methods for assessing visual function of infants.

T C Prager; Y L Zou; C L Jensen; J K Fraley; R E Anderson; W C Heird

doi:10.1016/s1091-8531(99)70023-6

Home/Archive/PubMed

PubMed · 10532572

Evaluation of methods for assessing visual function of infants.

T C Prager·Y L Zou·C L Jensen·J K Fraley·R E Anderson·W C Heird

View original source ↗Export metadata ↓

Abstract

PURPOSE: Commonly used behavioral and electrical testing methods for estimation of visual acuity and visual function in infants yield different estimates and may not accurately predict visual acuity and visual function in later life. Moreover, neither test-retest variability nor side-by-side comparisons of the various methods have been thoroughly evaluated in the same infant population. The purpose of this study was to provide such an evaluation. METHOD: The test-retest variability of visual acuity and visual function was evaluated for the Teller Acuity Card (TAC) procedure, sweep visual evoked potential (VEP), as well as latency and amplitude measured by transient pattern VEP. Groups of approximately 20 infants contributed test-retest data. Visual function estimated by the various methods in a larger group of infants (n = 118) was compared. Correlations between methods and the validity of the various methods to detect maturational changes between 4 and 8 months of age were also assessed. Administration of these tests was according to standard and usual procedures. RESULTS: The average percent difference between test and retest estimates of acuity as well as the SD was lowest for transient VEP latency (3%, 7% SD). The other methods were markedly more variable: sweep VEP (2%, 22% SD), TAC procedure (8%, 20% SD), and transient VEP amplitude (7.5%, 39% SD). Average coefficients of variation showed a similar trend: transient VEP latency, 8%; sweep VEP, 15%; TACs, 30%; and transient amplitude, 53%. Correlations among estimates by the methods were poor, but expected changes in visual maturation from 4 to 8 months of age were detected with all methods. CONCLUSIONS: All methods evaluated provide valid and reliable test-retest data for a group, but are less valid for estimating visual acuity and visual function of an individual subject. The poor correlations between any 2 of the testing methods suggest that each test assesses a different aspect of vision. Nonetheless, expected maturational changes between 4 and 8 months of age were readily detectable by all methods evaluated.

Explore related subjects

Aging Evoked Potentials, Visual Female Humans Infant Male Reproducibility of Results Vision Tests Visual Acuity Comparative Study Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.Research Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

T C Prager, Y L Zou, C L Jensen, J K Fraley, R E Anderson, W C Heird. 1999. Evaluation of methods for assessing visual function of infants.. https://doi.org/10.1016/s1091-8531(99)70023-6

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

An open benchmark and language models for AI in aging biology.

Over the past two decades, human aging has been characterized across DNA methylation, transcriptomic, proteomic, and clinical modalities, yet no benchmark evaluates whether AI systems can interpret these heterogeneous data types in the context of aging biology. We introduce LongevityBench, an open suite of 17 tasks spanning five biodata domains, and use it to assess 18 frontier AI systems from six developer teams. Despite recent advances in AI, no single model dominates all tasks, with omics-based age prediction being the hardest task regardless of scale. To test whether these gaps can be closed without frontier-scale resources, we fine-tuned a family of five multitask Longevity-LLMs on domain-specific aging data. The compact (0.6B-9B parameters) Longevity-LLMs matched or exceeded far larger frontier systems on LongevityBench, showing that general-purpose language models can be adapted to structured-omics tasks. We publicly release the benchmark, models, and Longevity Claw, an agentic research interface for aging researchers.

Aging↗

PubMed2026

Association between sirtuin 1 and markers of oxidative stress in master athletes.

BACKGROUND: Lifelong training in master athletes confers protective effects, promoting higher sirtuin levels and enhanced antioxidant capacity. Although Sirtuin 1 (SIRT1) is well studied, no previous study has examined the relationship between circulating SIRT1 levels and antioxidant defense variables in master athletes. PURPOSE: To compare and analyze the relationships between circulating levels of SIRT1 and variables related to antioxidant defense in master athletes (MA) and untrained middle-aged individuals (UMA). METHODS: Male MA (n = 42; 51.62 ± 7.33 years; ≥10 years of training and competition in running) and UMA (n = 15; 47.73 ± 8.52 years) were evaluated. Venous blood samples were collected for biochemical analyses of SIRT1, antioxidant enzymes, TBARS and F2-isoprostanes, 8-OHdG, and redox balance indexes. RESULTS: MA showed higher levels of SIRT1 (18.22 ± 4.53 vs. 6.08 ± 2.11 ng/mL; p < 0.0001), as well as of SOD, CAT, and GSH (p < 0.001), indicating a more favorable antioxidant profile. After adjustment for body fat percentage, differences in SOD, CAT, GSH and TBARS, remained significant. SIRT1 was positively correlated with SOD (r = 0.279; p = 0.031), CAT (r = 0.485; p < 0.001), GSH (r = 0.476; p < 0.001) and CAT/8-OHdG (r = 0.430; p = 0.032), and negatively correlated with TBARS (r = - 0.518; p < 0.001). CONCLUSION: Master athletes exhibited higher circulating SIRT1 concentrations and a more favorable systemic redox profile than untrained individuals, with SIRT1 being associated with markers of antioxidant defense, lipid peroxidation, and redox balance.

Aging↗

PubMed2026

Decoding SUMOylation as a metabolic stress sensor in aging and age-related disorders: Mechanisms, tissue specificity and therapeutic potential.

SUMOylation is a reversible post-translational modification increasingly recognized for its role in coordinating cellular responses to metabolic stress during aging. Emerging evidence indicates that it functions beyond a conventional modification, representing an adaptive stress‑responsive regulatory network that integrates metabolic, oxidative, inflammatory, and proteotoxic signals. Rather than acting on isolated pathways, this network finely tunes mitochondrial function, proteostasis, genome maintenance, immune balance, and epigenetic regulation. Accumulating evidence indicates that SUMO-dependent regulation exhibits remarkable tissue specificity, supporting mitochondrial adaptation and contractile integrity in skeletal muscle, shaping lipid and glucose metabolism in the liver, modulating proteotoxic stress and neuronal resilience in the brain, and contributing to immune cell differentiation and chronic low-grade inflammation during aging. In this review, we summarize current mechanistic insights into SUMO signaling across aging-relevant tissues, with particular emphasis on its functional interplay with other post-translational modifications, including ubiquitination and acetylation. We discuss how SUMOylation operates as a shared regulatory layer while enabling context-dependent outcomes that underlie diverse aging phenotypes and age-related disorders. Finally, we evaluate emerging translational approaches-ranging from pharmacological modulation of SUMO enzymes to lifestyle interventions such as caloric restriction and exercise-that highlight both the opportunities and challenges of targeting SUMO-regulated stress responses in aging. Together, this synthesis provides a framework for understanding how SUMOylation links metabolic stress to tissue-specific aging trajectories and therapeutic potential.

Aging↗